Should You Continue to Hold OMCL Stock in Your Portfolio Now?
Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.
OMCL - Omnicell, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$58.50
DETAILS
HIGH:
$70.00
LOW:
$49.00
MEDIAN:
$57.50
CONSENSUS:
$58.50
UPSIDE:
27.53%
Stock News
What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?
Shares of Omnicell OMCL have rallied 52.6% over the past year, significantly outperforming the industry's 20.8% fall and the S&P 500 composite's 23.9% gain.
Nnamdi Njoku Appointed President of Omnicell
FORT WORTH, Texas--(BUSINESS WIRE)--Nnamdi Njoku appointed President of Omnicell leading global operations & innovation strategy; Randall Lipps continues as CEO, Chairman of the Board.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Do Options Traders Know Something About Omnicell Stock We Don't?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks is more attractive to value investors?
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell: Why I'm Long Into Q2 Earnings Despite The Bookings Wobble
Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
FORTH WORTH, Texas--(BUSINESS WIRE)--Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business.
Top Robotics Stocks Worth Investing in the Second Half of 2026
Robotics stocks like ABB gain traction as 2026 marks a surge in AI-driven automation, new cobots and strategic deals shaping the sector's next growth wave.
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
A Look at Omnicell Inc (OMCL) After 4.1% Gain -- GF Value $38.65 vs Price $43.62
On June 04, 2026, Omnicell Inc (OMCL) shares rose 4.1% to a current price of $43.62. This performance comes amid a volatile trading period, with the stock's 52-
Is Omnicell Stock a Smart Addition to Your Portfolio Now?
OMCL rides on SaaS growth, Autonomous Pharmacy adoption and expansion plans, but rising costs and competition could test its momentum.
Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Omnicell (OMCL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
OMCL shares soar 57.3% in a year as SaaS growth, Autonomous Pharmacy momentum and OmniSphere adoption boost outlook.
Price Targets
Omnicell price target raised to $55 from $53 at Craig-Hallum
$55.00
(was $44.45)
Craig-Hallum
Omnicell price target raised to $70 from $60 at KeyBanc
$70.00
(was $44.31)
KeyBanc
Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet
$60.00
(was $35.10)
UBS
Omnicell price target lowered to $49 from $63 at Piper Sandler
$49.00
(was $39.08)
Piper Sandler
Omnicell (OMCL) PT Raised to $53 at BofA Securities
$53.00
(was $50.98)
UBS
Omnicell upgraded to Overweight from Sector Weight at KeyBanc
$60.00
(was $47.45)
KeyBanc
Omnicell price target raised to $52 from $43 at Wells Fargo
$52.00
(was $45.64)
Wells Fargo
Omnicell (OMCL) PT Lowered to $55 at Piper Sandler Despite Guide Raise
$55.00
(was $31.11)
Jessica Tassan
·
Piper Sandler
Omnicell upgraded to Overweight from Equal Weight at Wells Fargo
$35.00
(was $27.46)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target lowered to $40 from $49 at Wells Fargo
$40.00
(was $43.37)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target raised to $58 from $39 at Barclays
$58.00
(was $53.05)
Stephanie Davis
·
Barclays
Omnicell (OMCL) PT Raised to $61 at Piper Sandler
$61.00
(was $40.00)
Sean Wieland
·
Piper Sandler
Barclays Upgrades Omnicell (OMCL) to Equalweight
$39.00
(was $39.22)
Stephanie Davis
·
Barclays
JP Morgan Maintains Neutral on Omnicell, Lowers Price Target to $57
$57.00
(was $53.63)
J.P. Morgan
Omnicell price target lowered to $150 from $162 at Piper Sandler
$150.00
(was $109.12)
Jessica Tassan
·
Piper Sandler
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
$158.00
(was $109.82)
Stan Berenshteyn
·
Wells Fargo
Piper Sandler Maintains Overweight on Omnicell, Lowers Price Target to $162
$162.00
(was $114.90)
Piper Sandler